AbbVie ends work on cancer drug Rova-T after failures
AbbVie Inc. said it would stop all research on its experimental cancer treatment Rova-T, a drug it bought in its $5.8 billion 2016 takeover of Stemcentrx Inc.
More from Illinois Business
Illinois Farmer Today
Corn rootworm possesses 'secret weapon' to survive winter
Illinois Business
•
Aug 5, 2025